Group items tagged

ValueNetworks.com® — a leader in organizational network visualization and analysis applications — announces the Value Network Analysis Workshop: Optimizing Business Performance. The Value Network Analysis Workshop will be held at the MaRS Collaboration Center in Toronto, Ontario, Canada, on 20 March 2009. This workshop develops leadership, fluency and visualization expertise for value networks. It offers a hands-on introduction to social, organizational and value network analysis (VNA) application technology.

Manufacturers of human IVD technologies have been contributing their skills and knowledge more and more to the nonclinical and agricultural diagnostic markets.

To learn more about why IVD manufacturers are making the switch from human diagnostics and testing to agricultural and other nonclinical diagnostics, IVD Technology editor Richard Park spoke with Rocky Ganske, president and CEO of Axela Inc. (Toronto)

Our technology allows us to work directly in a variety of sample types that are difficult for other technologies to detect pathogens in without some additional sample preparation. So that led to people who were doing BSE (mad cow)–type testing asking if we could do tests for protein directly in matrices like milk or brain homogenate, and people asking for testing in plant extracts and things like that because other technologies don’t have that capacity.

MaRS Innovation and the Samuel Lunenfeld Research Institute of Mount Sinai Hospital are pleased to announce that they have entered into an agreement to collaboratively initiate commercialization of an umbilical cord stem cell technology for potential treatment in cardiovascular disease, diabetes and neurological disorders.

With the Toronto area identified as a world-leading cluster in stem cell research, we are extremely excited to have identified this technology as our first commercialization opportunity,” said Dr. Rafi Hofstein, President and CEO of MaRS Innovation.

MaRS Innovation, along with the inventors and Mount Sinai, will initially focus on the diabetes application for the technology, as research has demonstrated that these cells uniquely secrete insulin in response to glucose, thereby mimicking the “normal” physiological state.

Canada has always had to fight hard to attract talent and investment

MaRS Vital to Toronto's life sciences vision is MaRS (derived from Medical and Related Sciences) a non-profit organisation and business centre located in the heart of the city. Its core function is as a biotech incubator and business park, known as MaRS Discovery District. The venture was first established in 2000 to help foster and accelerate the growth of successful Canadian businesses and, after some uncertain times, it is now gathering momentum. A separate technology transfer office, MaRS Innovation, has also been established that, it is hoped, can be a world beater in its own right (see Turning good ideas into world beaters below). The location of the MaRS building in central Toronto is important, as it is just a stone's throw away from an existing cluster of universities and academic hospitals. MaRS has many links with other research-based organisations, including collaborations with three local universities, 10 academic teaching hospitals and the Ontario Institute for Cancer Research. MaRS occupies the Old Toronto general hospital, where insulin was first discovered by Best and Banting in 1921 and then developed for use in human trials. The 21st Century organisation can build on this heritage in patient-focused discovery and development. Formerly the head of venture capital firm Primaxis, Ilse Treurnicht is chief executive of MaRS Discovery District. She acknowledges the crisis in venture capital funding, and says Canada's sector has always had less access funds through this route than other countries. This is one of the drivers behind the search for a new approach. Treurnicht says the old models of building biotech and life sciences businesses have to be discarded, as they have failed to build companies with critical mass. She says MaRS' new 'Convergence Innovation' strategy of bringing science, capital and business together will pay off.

"We call our strategy 'Convergence Innovation' and what we are trying to do is move away from the old linear model of academics struggling in their spare time to build companies or entrepreneurs doing this in a very incremental way."It takes time and it has many risk points along the way. So using this Convergence centre model to create a much more dynamic organisation which can help accelerate good ideas towards the commercialisation." But she says Canada's geography and demographics are always going to be a challenge. "This is a very large country with a small population. If you think in terms of clusters and hub regions, Canada's business hubs are separated geographically, and there is not much in between in terms of people."That means we can't try to be a little United States, because we just won't show up on the radar. We have to take a different approach. We have to think about collaboration as our potential competitive advantage - that means using networks and associations to solve problems and build businesses."So as new opportunities emerge, we can take them to market faster and hopefully with a higher success rate." The centre currently accommodates numerous start up companies, as well as those providing legal and financial services to them. AstraZeneca and GlaxoSmithKline also have offices on site. In all, MaRS provides mentoring for over 200 different companies across Ontario, and runs courses on entrepreneurship and preparing products for market.

At the AlwaysOn Stanford Summit, Aeryon Labs President Dave Kroetsch gave a compelling pitch on his company, which makes a two-pound robot helicopter that has enough on-board intelligence and stability control to allow it to be flown by people who just point to locations on a Google Map-based interface.

sell to private security forces, and eventually police departments

other markets include construction (for site surveys), other public safety applications, and of course military.

Look who just landed on MaRS

MaRS was known for just that – putting a collective roof over the heads of Canada's out-of-this-universe thinkers. Aside from hosting the unlikely duo of Arnold Schwarzenegger and Dalton McGuinty at a funding announcement two years ago, the centre seems enveloped in galactic silence.

corner of College and University

the Chief of Research at the Hospital for Sick Children in Toronto, collaboration is the key to the future.

That's why Dr. Janet Rossant is so enthusiastic about the work being done in the MaRS Discovery District - a unique zone in the city where innovations in science and technology are commercialized through partnerships between researchers and private enterprise.

"The MaRS Centre and biomedical community have seen tremendous growth over the past few years," says Dr. Janet Rossant. "And it continues to grow." "This growth is attracting the world's best scientists to come work here, which is very exciting."